| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 113,390 | 112,970 | 98,980 | 97,310 | 95,780 |
| Sales Growth | +0.37% | +14.13% | +1.72% | +1.60% | -2.29% |
| Net Income | 6,500 | 1,350 | -510 | -16,480 | -2,290 |
| Net Income Growth | +381.48% | +364.71% | +96.91% | -619.65% | -8.02% |
Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Artivion Inc. is a medical device company. It focused on developing simple, elegant solutions which address cardiac and vascular surgeons. The company's group of products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts and surgical sealants. Artivion Inc., formerly known as CryoLife Inc., is headquartered in suburban Atlanta, Georgia.
Fiscal Year End Date: 12/31